Pharmaceutical

argenx’s VYVDURA gains approval in Japan for gMG treatment

Japan has approved argenx’s VYVDURA injection for subcutaneous administration to treat generalised myasthenia gravis (gMG) in adults.

Jan 19, 2024 - 18:00
argenx’s VYVDURA gains approval in Japan for gMG treatment
Japan has approved argenx’s VYVDURA injection for subcutaneous administration to treat generalised myasthenia gravis (gMG) in adults.
Read the original article

Tags:

Previous Article

BridgeBio secures $1.25bn for genetic therapy development

Next Article

Synendos set to study endocannabinoid inhibitor for neuropsychiatric conditions

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Roche drug slashes recurrence, death risk in lung cancer that afflicts younger patients

STAT+: Roche drug slashes recurrence, death risk in lun...

Oct 22, 2023

Psilocybin effective in treating depression

Psilocybin effective in treating depression

May 9, 2024

UK Spring Budget allocates funds to life sciences manufacturing

UK Spring Budget allocates funds to life sciences manuf...

Mar 5, 2024